THE US Food and Drug
Administration has expanded the
approved use of Stivarga
(regorafenib) to treat patients with
advanced gastrointestinal stromal
tumors that cannot be surgically
removed and no longer respond to
other FDA-approved treatments for
this disease.
Stivarga is a multi-kinase inhibitor,
blocks several enzymes that
promote cancer growth.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Mar 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Mar 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.